Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kaleidoscope platform study of amivantamab-based combinations in advanced unresectable lung cancer
ISRCTN23584582Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2022
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 2, open-label trial of amivantamab, capmatinib, cetrelimab and docetaxel in non-small cell lung cancer (NSCLC) (10 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of participants with adverse events by severity, Number of participants with dose-limiting toxicities and 1 more. Started Nov 2022; status: completed.
02
Drugs
amivantamabcapmatinibcetrelimabdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ISRCTN23584582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN23584582.